Tadalafil Tablet, Film Coated
Product Images NDC 51655-473

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 51655-473). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 473 54)

This is a description of a medication called Tadalafil. The tablets contain 20mg of Tadalafil USP and come in a package of 15. They should be stored at room temperature, away from children, in their original container. The tablets are film-coated and should not be split. The NDC number is 516§5-473-54 and the repackager is Northwind Pharmaceuticals. Along with the manufacturer's information, are details including the LCN number, lot number, and expiration date of the medication. The GTIN number is 0351655473542. The medication is only available with a prescription.*

FDA Label Image

Figure (Tadalafil Figure1)

This is a table that shows the difference in blood pressure (mmHg) between Tadalafil and Placebo. It includes measurements of standing systolic and diastolic BP, as well as supine systolic and diastolic BP, at different time intervals.*

FDA Label Image

Figure (Tadalafil Figure2)

The text seems to be a mixture of numerical data and some characters that may represent currency symbols, chemical names, or mathematical functions. It is not clear without further context what this information refers to, but it seems to involve some sort of experiment involving different treatments and their effects over time. Thus, a useful description of this text cannot be generated.*

FDA Label Image

Figure (Tadalafil Figure3)

The text represents a chart showing the changes in systolic blood pressure (measured in mmHg) over time after administration of different medications (20 mg tadalafil and/or 8 mg qd doxazosin) or placebo. The chart indicates the time of administration (08:00 or 20:00) for each medication or placebo.*

FDA Label Image

Figure (Tadalafil Figure4)

This is a graph displaying the plasma concentration of Tadalafil (in ug/L) over time (in hours) after administering different doses. The doses are a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dose for 5 consecutive days. The graph shows that the concentration of Tadalafil increases quickly after taking the drug and then gradually decreases over time. The highest concentration is achieved with the single 20-mg dose.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

The text describes the change from baseline in IPSS total score during a certain duration of treatment using tadalafils mg and a placebo. There was a statistically significant difference between the two, with the tadalafils mg group showing a greater improvement in scores. The duration of treatment was up to 12 weeks.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

FDA Label Image

Figure 7 (Tadalafil Figure7)

FDA Label Image

Figure 8 (Tadalafil Figure8)

FDA Label Image

Chemical Structure (Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.